By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical announced on Thursday that China's State Food & Drug Administration has approved its Ramp 200 Reader for marketing in China.

In a statement, Response Biomedical CEO S. Wayne Kay called the approval "a pivotal step forward in increasing our market penetration in this region."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.